BIOMAT Database Logo BIOMAT Database Logo

Acute leukaemia in bcr/abl transgenic mice. 1990

N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
Department of Pathology, Children's Hospital, Los Angeles, California 90027.

The Philadelphia chromosome, widely implicated in human leukaemia, is the result of a reciprocal translocation t(9;22) (q34;q11) in which the abl oncogene located at 9q34 is translocated to chromosome 22q11, where it is fused head-to-tail with 5' exons of the bcr gene. In acute lymphoblastic leukaemia, some patients have a breakpoint within the major breakpoint cluster region of the bcr gene, whereas others have the break within its first intron. This second type of translocation results in the transcription of a 7.0-kilobase chimaeric bcr/abl messenger RNA translated into a bcr/abl fusion protein, p190, which has an abnormal tyrosine kinase activity and is strongly autophosphorylated in vitro. We have generated mice transgenic for a bcr/abl p190 DNA construct and find that progeny are either moribund with, or die of acute leukaemia (myeloid or lymphoid) 10-58 days after birth. This finding is evidence for a causal relationship between the Philadelphia chromosome and human leukaemia.

UI MeSH Term Description Entries
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
BCR-ABL rearrangements in acute lymphoblastic leukaemia.
June 1991, Lancet (London, England),
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
February 2001, Cancer research,
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
August 1992, Cancer research,
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
Lymphoid tumorigenesis by v-abl and BCR-v-abl in transgenic mice.
January 1990, Current topics in microbiology and immunology,
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
The e19a2 bcr/abl breakpoint in acute lymphoblastic leukaemia.
August 2000, British journal of haematology,
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
IFN-alpha treatment of p190 bcr abl transgenic mice.
July 1994, International journal of oncology,
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice.
July 1992, Oncogene,
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
bcr-abl in chronic myeloid leukaemia.
August 1986, Lancet (London, England),
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
A bcr-v-abl oncogene induces lymphomas in transgenic mice.
July 1989, Molecular and cellular biology,
N Heisterkamp, and G Jenster, and J ten Hoeve, and D Zovich, and P K Pattengale, and J Groffen
A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic myelogenous leukaemia.
March 1997, British journal of haematology,
Copied contents to your clipboard!